[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","commit":"e03f56897d","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty approved products that had none","file":"src/data/spikes/breast-hr-positive.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Camizestrant\" }]"}]},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/spikes/breast-hr-positive.ts","type":"changed","fields":[{"field":"tldr","before":"\"An oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows.\"","after":"\"Camizestrant is an oral oestrogen-receptor degrader approved in September 2026 for a new kind of decision: switching treatment when a blood test shows resistance developing, before the cancer visibly grows.\""},{"field":"summary","before":"\"AstraZeneca's next-generation oral SERD. SERENA-6 randomised patients whose ctDNA acquired an ESR1 mutation during first-line AI + CDK4/6 to switch to camizestrant + CDK4/6: PFS 16.0 vs 9.2 months (HR 0.44). After a ...","after":"\"Camizestrant is AstraZeneca's next-generation oral SERD. SERENA-6 randomised patients whose ctDNA acquired an ESR1 mutation during first-line AI + CDK4/6 to switch to camizestrant + CDK4/6: PFS 16.0 vs 9.2 months (HR..."}]},{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/","commit":"f8e98e6f47","date":"2026-09-08","author":"Jude Gomila","message":"Spikes: HR+/HER2- and HER2+ breast cancer to TNBC depth (structured trial outcomes, dosing, toxicity, regulatory events)","file":"src/data/spikes/breast-hr-positive.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"code"},{"field":"modality"},{"field":"status"},{"field":"tldr"},{"field":"summary"},{"field":"mechanism"},{"field":"mechanismSteps"},{"field":"dosing"},{"field":"toxicity"},{"field":"approvals"},{"field":"regulatoryEvents"},{"field":"targets"},{"field":"technologies"},{"field":"companies"},{"field":"cancers"},{"field":"trials"},{"field":"terms"}]}]